CAR-NK
Chimeric Antigen Receptor Natural Killer (CAR-NK) cells are engineered NK cells that combine the innate cytotoxicity of NK cells with the specificity of CAR.
The concept of NK cell-based therapy dates back to early studies in the 1990s, with CAR-NK development accelerating in recent years due to advances in gene editing and cell engineering technologies.
Clinical trials have shown encouraging safety and efficacy profiles, positioning CAR-NK as a next-generation platform for targeted cancer treatment.
To empower innovation in NK cell-based therapies, Allianz Bio, in collaboration with ACRO Biosystems, provides a comprehensive range of research tools including CAR-NK-optimized stable cell lines, target antigens, cytokines, and gene editing reagents.
Our product portfolio is designed to support every stage of CAR-NK research and development—from discovery through clinical translation.
| Isolation | Culture media & Supplements | Activation | T cell engineering |
|---|---|---|---|
| • Magnetic beads | • Expansion Media CelThera™ NK Cell Expansion Medium (Phenol Red-free) CelThera™ NK Cell Expansion Kit (Phenol Red-free) |
• Streptavidin | • Nucleic acid removal |
| • Flow cytometry analysis | • Growth Factor | • Magnetic beads | • Gene editing enzyme (AAV titration kit) |
| • Streptavidin | • Cytokines | ||
| • CD Markers |
| CAR evaluation | Cell lines | Kits |
|---|---|---|
| • Car protein target | • Reporter cell line | • Residual kit |
| • MHC molecules | • Overexpression cell line | • ELIspot kit |
| • Anti-CD19 CAR | • Gene knockout cell line | • Biomarker ELISA kit |
| • Car linker antibody | • One-stop cell line solutions | |
| • Bispecific antibody |
Key Feature
- Enhanced Targeted Cytotoxicity – Combines NK cells’ natural killing ability with CAR’s tumor specificity for potent anti-cancer effects.
- Next-Generation Immunotherapy – Clinically validated with promising safety and efficacy in early-stage cancer trials.
- Comprehensive Research Tools – Includes CAR-NK–optimized stable cell lines, target antigens, cytokines, and gene editing reagents.
- Support Across R&D Stages –Products are tailored for all phases from discovery to clinical translation.
- Innovation-Driven Platform – Enables advancement of CAR-NK therapies through cutting-edge cell engineering technologies.
